<DOC>
	<DOCNO>NCT01819415</DOCNO>
	<brief_summary>The purpose trial detect influence omega-3 supplement vitreous level vascular endothelial growth factor ( VEGF ) exudative age-related macular degeneration ( AMD ) patient receive intravitreal anti-VEGF treatment . Patients randomize receive either Age-Related Eye Disease Study 1 ( AREDS-1 ) supplement formula addition Lutein AREDS-2 supplementation add Omega-3 metabolite ( DHA EPA ) formula . Our goal take limited volume vitreous sample patient previous regular anti-VEGF injection perform comprehensive cytokine lipidomic profiling . We hypothesize , base previous basic science discovery potent anti-VEGF action Omega-3 metabolite ( 4-HDHA ) , lipid metabolite composition metobolite level significantly vary accord VEGF level . Based result pioneer clinical study , research team proceed evaluate individual anti-angiogenic ( vessel growth stop ) property predominant Omega-3 metabolite find .</brief_summary>
	<brief_title>Omega-3 Supplementation Vitreal VEGF Levels Wet-AMD</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>wet AMD eligible intravitreal antiVEGF treatment . Confirmed exudation SDOCT . dry AMD . Disciform scar . Smokers . Morbid obesity . Patients undergoing form treatment wet AMD .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>wet AMD</keyword>
	<keyword>Omega-3</keyword>
	<keyword>VEGF</keyword>
	<keyword>Lipidomics</keyword>
	<keyword>DHA</keyword>
	<keyword>EPA</keyword>
</DOC>